00000nam 2200000za 4500 9.833934 CaOODSP 20221107150326 cr ||||||||||| 170327s2016 oncd os f000 0 eng d CaOODSP eng eng fre n-cn--- H82-25/2016-PDF Cost pressure of the new hepatitis C drugs in Canada [electronic resource] = Pressions exercées sur les coûts des nouveaux médicaments contre l’hépatite C au Canada. Pressions exercées sur les coûts des nouveaux médicaments contre l’hépatite C au Canada [Ottawa] : Patented Medicine Prices Review Board, [2016] [1] p. : col. charts Caption title. At head of title: National Prescription Drug Utilization Information System. "The pricing, utilization and cost related to the direct-acting antivirals (DAAs) for the treatment of hepatitis C has become a critical issue for public plans, private insurers and patients. This study provides insight into the use, pricing and cost of DAAs in Canada and internationally in 2015, along with a retrospective look at the recent trends. The international analysis focuses on the PMPRB7 countries: France, Germany, Italy, Sweden, Switzerland, the United Kingdom (UK) and the United States (US). Results for the Canadian market are reported at the national level, as well as for the private and public market segments." Text in English and French. gccst Hepatitis gccst Drugs gccst Prices Canada. Patented Medicine Prices Review Board. National Prescription Drug Utilization Information System (Canada) Cost pressure of the new hepatitis C drugs in Canada fre (CaOODSP)9.833936 PDF 313 KB https://publications.gc.ca/collections/collection_2017/cepmb-pmprb/H82-25-2016.pdf